Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.




) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.5%. By the end of trading, Gilead fell $1.01 (-1.6%) to $61.73 on light volume. Throughout the day, 5,296,113 shares of Gilead exchanged hands as compared to its average daily volume of 7,736,900 shares. The stock ranged in price between $61.71-$62.74 after having opened the day at $62.63 as compared to the previous trading day's close of $62.74. Other companies within the Drugs industry that declined today were:




), down 16.7%,

KaloBios Pharmaceuticals



), down 15.2%,

AMAG Pharmaceuticals



Scroll to Continue

TheStreet Recommends

), down 14.3% and

Clovis Oncology



), down 11.6%.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $95.8 billion and is part of the health care sector. Shares are up 70.4% year to date as of the close of trading on Tuesday. Currently there are 18 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates


as a


. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the positive front,

Pacific Biosciences of California



), up 72.8%,

GW Pharmaceuticals PLC ADR



), up 63.1%,




), up 21.1% and

Merus Labs International



), up 16.5% , were all gainers within the drugs industry with




) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.